SCHEMBL29702903

SCHEMBL29702903

Cc1ccccc1-c1cc(Oc2cccc(C(=O)O)c2)nc(NS(=O)(=O)c2cccc(N)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.43
▸ AKR1C3 P42330 3/20 0.41
▸ LOXL2 Q9Y4K0 2/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ CASP3 P42574 1/20 0.40
▸ SENP8 Q96LD8 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ F2 P00734 1/20 0.40
▸ F10 P00742 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ ACLY P53396 1/20 0.39
▸ CCR2 P41597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24330515 1.00 ALDH1A1 (0.43) ALDH1A1AKR1C3LOXL2KMT2AMEN1
SCHEMBL26807160 0.92 CA12 (0.41) ALDH1A1AKR1C3KMT2AMEN1TSHR
SCHEMBL24309603 0.91 POLB (0.45) ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL26807174 0.87 CA12 (0.39) ALDH1A1F2F10TSHRSMN1; SMN2
SCHEMBL26807133 0.86 PGR (0.42) TSHRSMN1; SMN2POLBCCR2
SCHEMBL29567277 0.86 PGR (0.42) TSHRSMN1; SMN2POLBCCR2
SCHEMBL26807167 0.86 MAPT (0.45) ALDH1A1TSHRSMN1; SMN2POLB
SCHEMBL26807176 0.84 PLA2G7 (0.46) KMT2AMEN1SMN1; SMN2POLB
SCHEMBL29567014 0.84 TSHR (0.39) ALDH1A1F2TSHRSMN1; SMN2POLB
SCHEMBL24309292 0.84 TSHR (0.39) ALDH1A1F2TSHRSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225763-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076626-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback